Information Provided By:
Fly News Breaks for September 20, 2017
Sep 20, 2017 | 07:24 EDT
SunTrust analyst Yatin Suneja says that Biogen's MS business faces "increasing market headwinds" but "remains very lucrative" and is poised to grow around 5% "over the next few years." The analyst adds that its "solid balance sheet provides M&A flexibility," while its Alzheimer's drug could generate $5B-$10B of revenue, which would enable the stock to rise 50%+. Target $360. .
News For BIIB From the Last 2 Days
There are no results for your query BIIB
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.